Recall Z-1049-2017— Endologix

Class II FDA medical device recall by Endologix, initiated 2017-01-04, terminated 2017-04-28. FDA's recall record names no specific 510(k) clearance for this event. Product: AFX2 Endovascular AAA System Item No. Item Description F00820-01 BEA28-120/I20-40 F00820-02 BEA28-100/I20-40 F00820-03 BEA28-80/I20-40 F00820-06 BEA28-120/I16-40 F00820-07 BEA28-100/I16-40 F00820-08 BEA28-80/I16-40 F00820-09 BEA28-60/I16-40 F00820-16 BEA28-110/I20-30 F00820-17 BEA28-90/I20-30 F00820-18 BEA28-70/I20-30 F00820-20 BEA28-110/I16-30 F00820-21 BEA28-90/I16-30 F00820-22 BEA28-70/I16-30 F00820-28 BEA25-120/I20-40 F00820-29 BEA25-100/I20-40 F00820-30 BEA25-80/I20-40 F00820-43 BEA25-110/I20-30 F00820-44 BEA25-90/I20-30 F00820-45 BEA25-70/I20-30 F00820-57 BEA22-80/I20-40 F00820-71 BEA22-90/I20-30 F00820-72 BEA22-70/I20-30 The AFX Endovascular AAA System is intended for endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms (AAA. Reason: Endologix updated information on the rates of Type III endoleaks and suggestions for patient surveillance and treatment..

Recalling firm

Endologix

Classification

Class II

Status

Terminated

Initiated

2017-01-04

Terminated

2017-04-28

Firm location

Irvine, CA, United States

Data sourced from openFDA. This site is unofficial and independent of the FDA.